Underperform Reiterated on Ardent: Aggressive EBITDA Targets and Reimbursement Risks Undermine Valuation

Analyst Kevin Fischbeck of Bank of America Securities reiterated a Sell rating on Ardent Health Partners, Inc., with a price target of $8.80.

Kevin Fischbeck has given his Sell rating due to a combination of factors tied to both guidance quality and reimbursement risk. While Ardent’s fourth-quarter EBITDA modestly topped expectations, revenues missed on weaker pricing, and management’s 2026 outlook implies EBITDA growth that appears overly ambitious once one adjusts for supplemental payments and various cost and reimbursement assumptions.

He notes that the company is counting on sizable cost savings from its IMPACT program to offset a larger-than-expected exchange-related headwind, with margins still projected to compress year over year. In Fischbeck’s view, this mix of conservative exchange assumptions, aggressive core EBITDA growth targets, and ongoing reimbursement and professional fee pressures supports a valuation below the current share price, leading him to reiterate an Underperform rating and maintain a price objective of $8.80.

Fischbeck covers the Healthcare sector, focusing on stocks such as Cigna, Humana, and Tenet Healthcare. According to TipRanks, Fischbeck has an average return of 3.2% and a 59.44% success rate on recommended stocks.